ReSTORE

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Individuals with Invasive Candidiasis

Diagnosis Required

Confirmed diagnosis of Invasive Candidiasis

Diseases Being Studied

Invasive Candidiasis
Location: San Antonio, TX

Sponsor: CidaraTherapeutics

Coordinating Center/CRO: WuXiAppTec

Primary Objective: Demonstrate that Rezafunginfor Injection is non-inferior to caspofunginfor all-cause mortality (ACM) at Day 30 (-2 days) in the modified intent-to-treat (mITT) population (United States Food and Drug Administration [FDA] primary objective—slightly different Primary Objective for EMA)

Study drugs: Rezafunginfor Injection

Sample size: 218

Inactivated

Meet Your Clinical Research Team

Contact us

Principal Investigator: Infectious Diseases Faculty

For more information, please contact Dr. Barbara Taylor